ARBUTUS BIOPHARMA CORP (ABUS)
Sector: Health Care
2026 Annual Meeting Analysis
ARBUTUS BIOPHARMA CORP · Meeting: May 26, 2026
Directors FOR
5
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Androski joined the board in February 2025 (less than 24 months ago), so she is exempt from the TSR performance trigger; she has strong relevant biotech and legal experience, attended all required meetings, and there are no overboarding, independence, or attendance concerns.
Beardsley joined in February 2025 (less than 24 months ago), making him exempt from the TSR trigger; he brings over 30 years of drug development and biotech company-building experience, is independent, serves on the Audit and Compensation Committees appropriately, and met the 75% meeting attendance threshold.
Bishop joined in February 2025 (less than 24 months ago), so he is exempt from the TSR trigger; he has relevant finance and portfolio management expertise qualifying him for his Audit Committee chairmanship, is independent under Nasdaq rules (with the board having considered his Roivant affiliation), and met attendance requirements.
Gline joined in February 2025 (less than 24 months ago), making him exempt from the TSR trigger; he brings relevant healthcare investing and operations experience as CEO of Roivant, is classified as independent by the board, and met all attendance requirements — noting his Roivant affiliation (Roivant holds ~20% of shares) was reviewed by the board in its independence assessment.
Sawhney joined in August 2025 (well under 24 months ago), so he is fully exempt from the TSR trigger; he has extensive healthcare executive and investment experience appropriate for a clinical-stage biotech, is independent, and met meeting attendance requirements.
All five director nominees joined the board in 2025, making each of them exempt from the TSR underperformance trigger under the 24-month new-director exemption. The stock's 3-year return of +51.6% vs. the S&P 500 (^GSPC — S&P 500) return of +67.8% represents a gap of only -16.2 percentage points, well below the 65-percentage-point threshold required to trigger a vote against directors even if the exemption did not apply. No overboarding, independence, attendance, or qualification concerns were identified. All five directors are supported.
Say on Pay
✓ FORCEO
Lindsay Androski
Total Comp
$1,369,013
Prior Support
N/A
CEO Lindsay Androski received total compensation of $1,369,013 for 2025, which reflects a partial year (she started February 25, 2025) and consists of $437,750 in salary, $714,751 in stock option awards (the reported value), and a $216,512 performance bonus earned at 110% of target — a reasonable pay level for a biotech CEO at an ~$850M company on a pro-rated basis. The pay mix is heavily weighted toward variable pay (option awards and performance bonus together represent roughly 68% of total compensation), exceeding the 50-60% variable pay threshold the policy looks for, and the annual bonus was tied to pre-established corporate objectives including litigation outcomes and clinical milestones. The company has a clawback policy adopted in October 2023 consistent with SEC and Nasdaq rules, and Arbutus's stock returned +51.6% over three years compared to +67.8% for the S&P 500 (^GSPC — S&P 500), a modest gap that does not trigger a pay-for-performance concern given that incentive pay was not above benchmark levels.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$622,000
Non-Audit Fees
$3,600
Non-audit fees of $3,600 represent less than 1% of audit fees of $622,000, far below the 50% threshold that would raise independence concerns. EY's tenure is not explicitly disclosed in the proxy so the tenure trigger cannot fire. EY is a Big 4 firm appropriate for a company of Arbutus's size. No material restatements were identified. All policy screens pass.
Overall Assessment
Arbutus Biopharma's 2026 annual meeting presents a straightforward ballot: all five director nominees joined the board in 2025 and are exempt from TSR scrutiny under the new-director exemption, the auditor (EY) passes all fee ratio and adequacy screens, and CEO pay is reasonable and appropriately structured for a partial-year appointment at a clinical-stage biotech. The only proposal outside current policy coverage is the new equity plan, which replaces two expiring plans and incorporates several shareholder-friendly features.
Compensation Peer Group
1 companies disclosed in 2026 proxy filing